AbbVie’s migraine treatment meets late-stage study goal
4 Articles
4 Articles
AbbVie’s migraine treatment meets late-stage study goal
(Corrects keyword used by media clients to "ABBVIE-MIGRAINE/STUDY" from "ABBVIE-MIGRANE STUDY/") Sept 10 (Reuters) - AbbVie said on Thursday its migraine treatment had met the main goal of a late-stage study testing it as a preventive trea...
A large clinical trial has shown encouraging results for the treatment of menstrual migraine, a type of migraine that often causes more severe and persistent attacks. AbbVie announced that atogepant met its primary endpoint in the Phase 3 LUNA study, significantly reducing migraine days during the period around menstruation […] The article Period migraine: New treatment reduces attacks in large clinical trial appeared first on the Free Press.
AbbVie Gains as Qulipta Opens a New Migraine Market
This article first appeared on GuruFocus. AbbVie (NYSE:ABBV), the global immunology and pharmaceutical company, said Qulipta achieved the main goal of a Phase 3 trial targeting menstrual migraine. Shares traded at $252.25 Thursday morning, up approximately 0.4%. Warning! GuruFocus has detected 5…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
